MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
What It Is
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome. It is one of the few known mitochondria-derived peptides (MDPs) with systemic signaling activity. Research has demonstrated its role in metabolic regulation, exercise mimicry, and insulin sensitivity. Circulating MOTS-c levels decline measurably with age, placing it at the forefront of longevity research in 2026. A 2025 study published in Experimental & Molecular Medicine demonstrated that MOTS-c prevents pancreatic islet cell senescence by modifying senescence-associated transcriptional and metabolic profiles in β-cells, delaying diabetes progression in animal models. A separate 2025 study in Frontiers in Physiology showed MOTS-c restores mitochondrial respiration in type 2 diabetic heart tissue, expanding its therapeutic relevance to cardiovascular metabolic disease. In sedentary animal models, exogenous MOTS-c reproduced training-induced metabolic adaptations, earning it the label 'exercise mimetic peptide.' Updated research confirms skeletal muscle MOTS-c levels increase nearly 12-fold during exercise. Exogenous MOTS-c doubled running capacity in mice and reversed age-related physical decline by activating the AMPK/PGC-1α pathway and directly binding casein kinase 2 (CK2). Notably, circulating MOTS-c levels are significantly higher in centenarian populations compared to age-matched controls, suggesting maintained MOTS-c signaling may serve as both a biomarker and driver of successful metabolic aging. A key challenge for clinical translation is MOTS-c's low bioavailability, poor stability, and short half-life — limitations common to mitochondrial-derived peptides that have slowed clinical development. As of April 2026, no active MOTS-c human trials are registered on ClinicalTrials.gov, though a trial using a MOTS-c analog for fatty liver and obesity (NCT03998514) has been registered. MOTS-c is scheduled for PCAC review on July 23, 2026, alongside BPC-157, KPV, and TB-500, to determine whether it can be legally compounded under section 503A. A 2026 study in ScienceDirect examined MOTS-c's role in type 2 diabetes mellitus complications including cardiovascular disease, establishing MOTS-c as a multi-organ protective factor whose deficiency correlates with cardiometabolic risk. Public comments via docket FDA-2025-N-6895 are accepted until July 22, 2026.
Regulatory Status
Moved from Category 2 back to Category 1 per HHS announcement February 27, 2026. FDA PCAC will review MOTS-c (free base and acetate) on July 23, 2026 for potential 503A Bulks List inclusion for obesity and osteoporosis indications. Public comment docket FDA-2025-N-6895 open until July 22, 2026.
Effective: February 2026
View FDA SourceEvidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Animal (mouse) | Age-dependent physical decline — MOTS-c administration | Doubled running capacity; reversed age-related decline via AMPK/PGC-1α pathway | Source |
| Animal (mouse, 2025) | Pancreatic islet cell senescence — diabetes model | MOTS-c prevented β-cell senescence and delayed diabetes progression by modifying senescence-associated transcriptional and metabolic profiles | Source |
| Animal (mouse, 2025) | Type 2 diabetic heart — mitochondrial respiration | MOTS-c restored mitochondrial respiration in diabetic cardiac tissue | Source |
| Observational (human cohort) | Centenarian populations vs age-matched controls | Significantly higher circulating MOTS-c levels in centenarians, suggesting maintained MOTS-c signaling as biomarker of successful metabolic aging | Source |
| Review/Preclinical (2026) | MOTS-c in T2DM — risk factors to cardiac complications | MOTS-c deficiency correlates with cardiometabolic risk; multi-organ protective effects documented across diabetic complications | Source |
Commonly Discussed Benefits
Researching MOTS-c? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Discovery is recent; most data is preclinical
- No completed human clinical trials
- Long-term effects unknown
- Not FDA-approved for any indication
- Unlike small-molecule metabolic compounds such as SLU-PP-332 and 5-Amino-1MQ, MOTS-c IS on the FDA's July 23, 2026 PCAC compounding review list — a favorable vote would not legitimize those other compounds
Comparisons
See how MOTS-c compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 PubMed
- [2] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 PubMed
- [3] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 PubMed
- [4] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 PubMed
- [5] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 PubMed
- [6] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee PubMed
- [7] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) PubMed
Keep researching in the app
- Log MOTS-c to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
SS-31
High EvidenceA mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.
NAD+
Medium EvidenceA coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.
5-Amino-1MQ
Low EvidenceA small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.
SLU-PP-332
Low EvidenceA synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health.
Humanin
Low EvidenceAn endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians.